US2017296624A1PendingUtilityA1
Gla domains as targeting agents
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61P 9/10A61P 43/00A61P 7/04A61P 9/00A61P 5/38A61P 37/02A61P 7/00A61P 37/06A61P 3/10A61P 7/02A61P 7/06A61P 37/00A61P 5/14A61P 35/00A61P 31/22A61P 31/16A61P 31/18A61P 31/04A61P 29/00A61P 3/00A61P 31/20A61P 31/12A61P 25/02A61P 31/14A61P 31/00A61P 3/02A61P 21/00A61P 17/06A61P 13/12A61P 21/02A61P 1/16A61P 17/00A61P 1/14A61P 17/14A61P 25/00A61P 21/04A61P 1/04A61P 19/02C12N 9/6424C12Y 304/21021C12N 9/6429C12Y 304/21005C07K 14/745C12N 9/6437A61K 38/1709A61K 38/16A61K 45/06C07K 14/485A61K 47/642C07K 2319/035A61N 5/10A61K 38/1808Y02A50/30
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Claims
exact text as granted — not AI-modified1 - 26 . (canceled)
27 . A method of treating cancer, an autoimmune disease, a viral disease, a hypercoagulation disorder, sepsis, or a vaso-occlusive crisis in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
28 . (canceled)
29 . The method of claim 27 , wherein said method comprises treating cancer, further comprising treating said subject with a second cancer therapy.
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . The method of claim 27 , wherein said method comprises treating the autoimmune disease, further comprising treating said subject with a second autoimmune disease therapy.
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . The method of claim 27 , wherein said method comprises treating the viral disease, further comprising treating said subject with a second anti-viral therapy.
38 . (canceled)
39 . (canceled)
40 . The method of claim 27 , wherein said method comprises treating the hypercoagulation disorder, further comprising treating said subject with a second anti-coagulant.
41 . A method of modulating clotting in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
42 . The method claim 41 , further comprising administering to said subject a clotting factor.
43 . (canceled)
44 . (canceled)
45 . A method treating a disorder characterized by pathologic expression of phosphatidylserine on the surface of a cell comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
46 . The method of claim 27 , wherein said method comprises treating cancer.
47 . The method of claim 27 , wherein said method comprises treating the autoimmune disease.
48 . The method of claim 27 , wherein said method comprises treating the viral disease.
49 . The method of claim 27 , wherein said method comprises treating the hypercoagulation disorder.
50 . The method of claim 27 , wherein said method comprises treating sepsis.
51 . The method of claim 27 , wherein said method comprises treating the vaso-occlusive crisis, and wherein the subject is a sickle cell subject.Join the waitlist — get patent alerts
Track US2017296624A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.